2022
SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure ∗
Ahmad T, Desai NR, Velazquez EJ. SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure ∗. Journal Of The American College Of Cardiology 2022, 80: 1311-1313. PMID: 36041913, DOI: 10.1016/j.jacc.2022.08.005.Peer-Reviewed Original ResearchDiabetes Mellitus, Type 2GlucoseHeart FailureHumansSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsStroke VolumeMedicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin Receptor AntagonistsDrug CostsDrugs, GenericHealth ExpendituresHeart FailureHumansMedicare Part DSodium-Glucose Transporter 2 InhibitorsStroke VolumeUnited StatesConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication pricesElectronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial
Ghazi L, Yamamoto Y, Riello RJ, Coronel-Moreno C, Martin M, O'Connor KD, Simonov M, Huang J, Olufade T, McDermott J, Dhar R, Inzucchi SE, Velazquez EJ, Wilson FP, Desai NR, Ahmad T. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial. Journal Of The American College Of Cardiology 2022, 79: 2203-2213. PMID: 35385798, DOI: 10.1016/j.jacc.2022.03.338.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Arrhythmia AgentsCardiotonic AgentsDiabetes Mellitus, Type 2ElectronicsFemaleHeart FailureHumansMaleOutpatientsSodium-Glucose Transporter 2 InhibitorsStroke VolumeVentricular Dysfunction, LeftVentricular Function, LeftConceptsGuideline-directed medical therapyUsual careEjection fractionHeart failureMedical therapyPrimary outcomeCluster-randomized comparative effectiveness trialSodium-glucose cotransporter 2 inhibitorsElectronic health record alertsAldosterone system inhibitorsReduced ejection fractionUsual care armCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsVentricular ejection fractionComparative effectiveness trialNumber of patientsKnowledge of guidelinesLow-cost interventionCare armDays postrandomizationEligible patientsGDMT useFailure therapyPatient characteristics
2021
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial
Sharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George JT, Hantel S, Desai N, Mentz RJ. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial. JACC Heart Failure 2021, 9: 568-577. PMID: 34325887, DOI: 10.1016/j.jchf.2021.03.003.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesDiabetes Mellitus, Type 2Double-Blind MethodFemaleHeart FailureHumansPhenotypeSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeConceptsCV deathLatent class analysisTreatment effectsNon-coronary artery diseaseEMPA-REG OUTCOME trialAdvanced coronary diseaseEMPA-REG OUTCOMESGLT-2 inhibitionGlomerular filtration rateType 2 diabetesEmpagliflozin 25EMPA-REGCV diseaseCV riskLower eGFRT2D durationOlder patientsOutcome trialsYounger patientsArtery diseaseCoronary diseaseCox regressionFiltration rateCardiovascular diseaseGroup 2Setting the Stage for a Multimarker-Based Heart Failure Prevention Trial? ∗
Ahmad T, Felker GM. Setting the Stage for a Multimarker-Based Heart Failure Prevention Trial? ∗. JACC Heart Failure 2021, 9: 224-225. PMID: 33632419, DOI: 10.1016/j.jchf.2021.01.001.Peer-Reviewed Original ResearchCardiovascular DiseasesDiabetes Mellitus, Type 2Heart FailureHumansSodium-Glucose Transporter 2 Inhibitors